Spero Therapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
In July 2026, Spero entered exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready anti-CD40L antibody, retaining rights outside Greater China. In June 2026, FDA approved Utebzi (tebipenem pivoxil), first oral carbapenem for complicated UTIs, with GSK holding U.S./European commercialization rights. Simultaneously, Spero closed $105M non-recourse royalty financing from HCRx (KKR affiliate) backed by future Utebzi GSK proceeds, structured to preserve 35% upside after debt repayment, extending cash runway to H2 2029.
Why this rating
Three major catalysts: (1) $105M financing = 65% of market cap, materially extends runway; (2) Utebzi FDA approval validates commercialization path; (3) SP001 acquisition adds pipeline asset. Relative to $160M company size, these are substantial. However, GSK controls U.S. Utebzi commercialization and company is still pre-revenue operationally.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.